Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

Cited In for PubMed (Select 19406209)

1.

Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Han S, Brenner JC, Sabolch A, Jackson W, Speers C, Wilder-Romans K, Knudsen KE, Lawrence TS, Chinnaiyan AM, Feng FY.

Neoplasia. 2013 Oct;15(10):1207-17.

2.

Molecular heterogeneity in mucoepidermoid carcinoma: conceptual and practical implications.

Bell D, El-Naggar AK.

Head Neck Pathol. 2013 Mar;7(1):23-7. doi: 10.1007/s12105-013-0432-5. Epub 2013 Mar 5. Review.

3.

Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Drake JM, Graham NA, Stoyanova T, Sedghi A, Goldstein AS, Cai H, Smith DA, Zhang H, Komisopoulou E, Huang J, Graeber TG, Witte ON.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1643-8. doi: 10.1073/pnas.1120985109. Epub 2012 Jan 17.

4.

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, Chinnaiyan AM.

Cancer Res. 2012 Apr 1;72(7):1608-13. doi: 10.1158/0008-5472.CAN-11-3648. Epub 2012 Jan 27.

5.

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.

Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF.

Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.

6.

Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.

Mitani Y, Rao PH, Futreal PA, Roberts DB, Stephens PJ, Zhao YJ, Zhang L, Mitani M, Weber RS, Lippman SM, Caulin C, El-Naggar AK.

Clin Cancer Res. 2011 Nov 15;17(22):7003-14. doi: 10.1158/1078-0432.CCR-11-1870. Epub 2011 Oct 5.

7.

Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.

Yan J, Diaz J, Jiao J, Wang R, You J.

J Biol Chem. 2011 Aug 5;286(31):27663-75. doi: 10.1074/jbc.M111.246975. Epub 2011 Jun 7.

8.

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.

Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557.

9.

How does DNA break during chromosomal translocations?

Nambiar M, Raghavan SC.

Nucleic Acids Res. 2011 Aug;39(14):5813-25. doi: 10.1093/nar/gkr223. Epub 2011 Apr 15. Review.

10.

The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers.

Zhang Y, Gostissa M, Hildebrand DG, Becker MS, Boboila C, Chiarle R, Lewis S, Alt FW.

Adv Immunol. 2010;106:93-133. doi: 10.1016/S0065-2776(10)06004-9. Review.

11.

Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer.

Chari R, Thu KL, Wilson IM, Lockwood WW, Lonergan KM, Coe BP, Malloff CA, Gazdar AF, Lam S, Garnis C, MacAulay CE, Alvarez CE, Lam WL.

Cancer Metastasis Rev. 2010 Mar;29(1):73-93. doi: 10.1007/s10555-010-9199-2. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk